Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review
Tang, Justin , Campian, Jian , Amin, Md Al, Amin, Md. Al

Vaccines | May 15, 2025 | Volume: 13 | Issue: 5 | Pages: 524

10.3390/vaccines13050524 | PMID 40432133 Get It

Over the past several decades, viral vector-based vaccines have emerged as some of the most versatile and potent platforms in modern vaccinology. Their capacity to deliver genetic material encoding target antigens directly into host cells enables strong cellular and humoral immune responses, often superior to what traditional inactivated or subunit vaccines can achieve. This has accelerated their application to a wide array of pathogens and disease targets, from well-established threats like HIV and malaria to emerging infections such as Ebola, Zika, and SARS-CoV-2. The COVID-19 pandemic further highlighted the agility of viral vector platforms, with several adenovirus-based vaccines quickly authorized and deployed on a global scale. Despite these advances, significant challenges remain. One major hurdle is pre-existing immunity against commonly used vector backbones, which can blunt vaccine immunogenicity. Rare but serious adverse events, including vector-associated inflammatory responses and conditions like vaccine-induced immune thrombotic thrombocytopenia (VITT), have raised important safety considerations. Additionally, scaling up manufacturing, ensuring consistency in large-scale production, meeting rigorous regulatory standards, and maintaining equitable global access to these vaccines present profound logistical and ethical dilemmas. In response to these challenges, the field is evolving rapidly. Sophisticated engineering strategies, such as integrase-defective lentiviral vectors, insect-specific flaviviruses, chimeric capsids to evade neutralizing antibodies, and plug-and-play self-amplifying RNA approaches, seek to bolster safety, enhance immunogenicity, circumvent pre-existing immunity, and streamline production. Lessons learned from the COVID-19 pandemic and prior outbreaks are guiding the development of platform-based approaches designed for rapid deployment during future public health emergencies. This review provides an exhaustive, in-depth examination of the historical evolution, immunobiological principles, current platforms, manufacturing complexities, regulatory frameworks, known safety issues, and future directions for viral vector-based vaccines.
Amyloid beta peptides inhibit glucose transport at the blood-brain barrier by disrupting the insulin-AKT pathway
Wang, Lushan , Curran, Geoffry L., Zhong, Rui , Zheng, Xue , Veerareddy, Vaishnavi, Thieschafer, Josslen S., Min, Hoon‐Ki , Lowe, Val J. , Kandimalla, Karunya K. , Kandimalla, Karunya K , Min, Hoon-Ki Paul , Xue, Zheng, Li, Ling

Journal of Cerebral Blood Flow & Metabolism | May 15, 2025 | Volume: 45 | Issue: 10 | Pages: 1961-1979

10.1177/0271678x251332493 | PMID 40370301 Get It

Abstract Molecular mechanisms underlying disruptions in brain glucose uptake and metabolism, linked with cognitive decline in Alzheimer’s disease (AD) patients, are only partially understood. This study investigated how soluble amyloid beta (sAβ) peptides affect glucose transport at the blood-brain barrier (BBB), the primary portal for glucose entry into the brain. We demonstrated that [ 18 F]-fluorodeoxyglucose ( 18 FDG) uptake is reduced in sAβ overproducing APP,PS1 transgenic mice compared to wild-type mice. Moreover, the influx rate of 18 FDG decreased in sAβ40 or sAβ42 pre-infused mice, highlighting the inhibitory effect of sAβ peptides on glucose transport at the BBB. Consistently, the expression of GLUT1, the primary glucose transporter at the BBB, is reduced in polarized human cerebral microvascular endothelial cell (hCMEC/D3) monolayers upon exposure to sAβ peptides and in Aβ-laden cerebral vasculature in vivo. The study further examined the influence of sAβ on the insulin-AKT pathway, known to regulate glucose uptake through modulation of thioredoxin-interacting protein (TXNIP) expression. Results showed that sAβ peptides suppress AKT phosphorylation and reduce GLUT1 expression by upregulating TXNIP levels in hCMEC/D3 monolayers. Co-incubation of resveratrol with sAβ peptides reduced TXNIP expression and rectified reductions in GLUT1 expression. In summary, toxic sAβ impairs BBB glucose transport by disrupting the insulin/AKT/TXNIP axis.
Propofol-associated Hypertriglyceridemia: Development and Multicenter Validation of a Machine-Learning-Based Prediction Tool
Deng, Jiawen , Heybati, Kiyan , Poudel, Keshav , Xie, Guozhen , Zuberi, Eric , Simha, Vinaya , Yadav, Hemang , Deng, J , Zuberi, Eric C.

Journal of Intensive Care Medicine | May 15, 2025 | Volume: 40 | Issue: 11 | Pages: 1159-1168

10.1177/08850666251342559 | PMID 40370218 Get It

Purpose: To develop and validate an explainable machine learning (ML) tool to help clinicians predict the risk of propofol-associated hypertriglyceridemia in critically ill patients receiving propofol sedation. Methods: Patients from 11 intensive care units (ICUs) across five Mayo Clinic hospitals were included if they met the following criteria: a) ≥ 18 years of age, b) received propofol infusion while on invasive mechanical ventilation for ≥24 h, and c) had a triglyceride level measured. The primary outcome was hypertriglyceridemia (triglyceride >400 mg/dL) onset within 10 days of propofol initiation. Both COVID-inclusive and COVID-independent modeling pipelines were developed to ensure applicability post-pandemic. Decision thresholds were chosen to maintain model sensitivity >80%. Nested leave-one-site-out cross-validation (LOSO-CV) was used to externally evaluate pipeline performance. Model explainability was assessed using permutation importance and SHapley Additive exPlanations (SHAP). Results: Among 3922 included patients, 769 (19.6%) developed propofol-associated hypertriglyceridemia, and 879 (22.4%) had COVID-19 at ICU admission. During nested LOSO-CV, the COVID-inclusive pipeline achieved an average AUC-ROC of 0.71 (95% confidence interval [CI] 0.70–0.72), while the COVID-independent pipeline achieved an average AUC-ROC of 0.69 (95% CI 0.68–0.70). Age, initial propofol dose, and BMI were the top three most important features in both models. Conclusion: We developed an explainable ML-based tool with acceptable predictive performance for assessing the risk of propofol-associated hypertriglyceridemia in ICU patients. This tool can aid clinicians in identifying at-risk patients to guide triglyceride monitoring and optimize sedative selection.
Outcomes and Characteristics of Mesenchymal Tumors Involving the Parotid Gland
Baratz, Hannah , Moore, Eric J. , Molligan, Jeremy , Tasche, Kendall K. , Abel, Kathryn M. Van , Baratz, Hannah Q , Yin, Linda X , Van Abel, Kathryn M , Yin, Linda X. , Price, Daniel L.

Annals of Otology, Rhinology & Laryngology | May 15, 2025 | Volume: 134 | Issue: 8 | Pages: 583-587

10.1177/00034894251336840 | PMID 40370050 Get It

Background: Malignant mesenchymal tumors involving the parotid gland are uncommon, characteristically aggressive, and little is known with few reports documented. Study Design: Retrospective case series. Setting: Single institution tertiary care center, 2010 to 2022. Method: Patients were identified from an institutional parotid tumor database. Patient history, demographics, pathologic diagnosis, treatment, and follow up were documented. Results: Eight patients were identified, 3 were males. The average age was 61 years old, and the most common tumors identified were pleomorphic sarcomas (3 patients). Presenting symptoms included: preauricular/cheek mass in 7 patients, facial pain (4), otalgia (4), aural fullness (3), and numbness (1). All patients received a parotidectomy, and 4 patients received adjuvant therapy of either radiation or chemoradiation. Post-operatively, there were 3 cases of distant recurrence, 2 cases of regional recurrence, and 1 case of local recurrence. There were 2 reports of death. Conclusion: Malignant mesenchymal tumors of the parotid are rare, represent varied histologies. Due to their aggressive nature, surgical resection with radiation and close follow-up may be an appropriate treatment regimen in controlling the disease.
Dual ProGlide Versus ProGlide and Angio‐Seal for Femoral Access Hemostasias in Transcatheter Aortic Valve Replacement: A Meta‐Analysis of Up‐to‐Date Evidence
Naeem, Farhan , Burhan, Muhammad , Qamar, Usama , Abramov, Dmitry , Burhan, Muhammad , Qamar, Usama , Alraies, M Chadi , Tabassum, Shehroze

Catheterization and Cardiovascular Interventions | May 15, 2025 | Volume: 106 | Issue: 1 | Pages: 621-624

10.1002/ccd.31577 | PMID 40370009 Get It

Inactivation of Histone Chaperone HIRA Unmasks a Link Between Normal Embryonic Development of Melanoblasts and Maintenance of Adult Melanocyte Stem Cells
Jaber‐Hijazi, Farah , Arnold, Rouven, Swaminathan, Karthic , Gilroy, Kathryn , Lagnado, Anthony B. , Kirschner, Kristina , Robertson, Neil , Reid, Claire , Fullarton, Neil J., Baranyk, Ian J , Shi, Christina Huan , Yip, Kevin Y. , Mesirov, Jill P. , Kirschner, Kristina , Robertson, Neil A , Rai, Taranjit Singh , Baranyk, Ian , Yip, Kevin Y , Passos, João F , Adams, Peter , Wenzel, Alexander T. , Reid, Claire, Pawlikowski, Jeff S. , Blyth, Karen , Harris, Melissa L. , Passos, João F. , Machesky, Laura M. , Adams, Peter D.

Aging Cell | May 15, 2025 | Volume: 24 | Issue: 7 | Pages: No page available

10.1111/acel.70070 | PMID 40669469 Get It

ABSTRACT Evidence indicates that the integrity of in utero development influences late life healthy or unhealthy aging; however, specific links between them are unclear. Histone chaperone HIRA is thought to play a role in both life stages, and here, we explore this role using the murine pigmentary system by investigating and comparing the effects of its lineage‐specific knockout, either conditionally during embryogenesis or postnatally. Embryonic knockout of Hira in tyrosinase+ neural crest‐derived lineages, including melanoblasts, led to reduced melanoblast numbers during embryogenesis, with single‐cell RNA sequencing analysis indicating evidence of lineage‐specificity defects. This was supported in an in vitro model using melb‐a melanoblasts in which Hira knockdown affected lineage identity and melanoblast differentiation potential, with ATAC‐seq data indicating a role of HIRA in orchestrating chromatin accessibility. Interestingly, however, newborn Hira knockout mice had wild type numbers of differentiated melanocytes, albeit functionally defective, as demonstrated by very mild hypopigmentation of the first hair coat, increased melanocyte telomere‐associated DNA damage foci, and impaired response to proliferative challenge. Moreover, as they aged, mice with embryonic melanoblast Hira knockout displayed marked defects in melanocyte stem cell maintenance and premature hair graying. Importantly, this phenotype was not observed after postnatal inducible knockout, indicating an essential role for HIRA at embryonic stages that is transmitted to adulthood, rather than a direct postnatal requirement within the pigmentary system. This genetic model shows that HIRA function during early development lays a foundation for maintaining lineage identity and subsequent maintenance of adult tissue‐specific stem cells during aging.
How do we put meaning into meaningful benefit? Perspectives from the lived experience
Paulsen, Russ , Romano, Carla (DeMuro), Frangiosa, Terry, Mordin, Margaret , Dardis, Gabrielle J., DiBenedetti, Dana , Petersen, Ronald C. , Cummings, Jeffrey L., DeMuro, Carla , Dardis, Gabrielle

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 15, 2025 | Volume: 11 | Issue: 2 | Pages: No page available

10.1002/trc2.70095 | PMID 40376143 Get It

Abstract Meaningful benefit is a much‐debated concept in Alzheimer's disease (AD). Research to date has primarily focused on change thresholds that are anchored in clinicians’ or care partners’ impressions; however, these thresholds are not inherently meaningful to people living with AD (PLWAD) and may not take their perspectives into account. By overlaying the lived experience of AD through the eyes of individual PLWAD and their care partners with clinical outcomes, we offer an important framework in which to consider meaningful benefit in terms of symptoms, functioning, and outcomes. The PLWAD and care partner interviews and surveys of the What Matters Most (WMM) research program have identified treatment‐related needs, preferences, and priorities of people at risk of or living with AD and their care partners across the AD continuum. A WMM conceptual model of disease—created and refined through interviews with PLWAD and care partners across the AD severity spectrum—includes 50 concepts across six domains (social life/activities, thought processing, communication, daily activities, mood/emotion, and general independence) considered important to all PLWAD and care partners. From the PLWAD and care partner perspectives, an increase in time to the onset, development, or worsening of the symptoms in any of these meaningful concepts was considered a meaningful benefit. No single commonly used clinical outcome assessment captures all concepts of importance, nor the importance of time in AD; considering the lived experience and priorities of individuals affected by AD is crucial to put the “meaning” in “meaningful.”
The core competencies in hospital medicine: Procedures 2025 update
Nichani, Satyen , Brooks, Megan , Bryson, Christine , Fitterman, Nick, Issa, Meltiady , Lukela, Michael, Marzano, Nick, Sopko, Kelly, Sweigart, Joseph R.

Journal of Hospital Medicine | May 15, 2025 | Volume: 21 | Issue: 4 | Pages: 423-434

10.1002/jhm.70042 | PMID 40369813 Get It

Abstract This article presents an updated framework from the Society of Hospital Medicine for individual learning objectives related to key procedures in hospital medicine. Building upon the 2017 framework, these objectives have been revised to reflect evolving clinical evidence, advancements, and shifts in hospital medicine practice patterns. The methodology included a comprehensive literature review, expert consensus panels, and feedback from practicing hospitalists across diverse clinical settings. The updated learning objectives address procedural competencies for the most common interventions in hospital medicine, including arthrocentesis, emergency procedures, interpretation of chest radiographs and electrocardiograms, lumbar puncture, paracentesis, thoracentesis, and vascular access. These revised learning objectives provide a framework to guide curricular development, continuing medical education, and hospital medicine practitioners in developing and maintaining procedural competence essential for high‐quality inpatient care.
The Role of Stromal Tumor Environment in Advancing Skin Cancer Diagnosis and Treatment
Jing, Frank Z. , Pazhava, Ani , Shachaf, Catherine M. , Meves, Alexander , Jing, Frank Z , Shachaf, Catherine

International Journal of Dermatology | May 15, 2025 | Volume: 64 | Issue: 11 | Pages: 2019-2028

10.1111/ijd.17827 | PMID 40369720 Get It

ABSTRACT The stromal tumor environment (STE) plays a vital yet often underrecognized role in cancer progression, shaping tumor development. It influences complex interactions among stromal cells, immune cells, extracellular matrix (ECM) components, and signaling molecules. Stromal cells regulate integrin signaling and are involved in remodeling the tumor microenvironment, driving critical processes such as cell migration, survival, angiogenesis, and proliferation. Advances in understanding the STE are creating new opportunities for early cancer detection and treatment. Innovations in molecular imaging, particularly for melanoma, are transforming cancer diagnostics by providing deeper insights into tumor biology, cellular interactions, and angiogenesis, paving the way for more personalized and timely therapeutic interventions. Among these advancements, in vivo skin fluorescent imaging (SFI) stands out as a powerful tool, offering real‐time molecular insights at the point of care with the ability to improve patient management.
Reply to Letter: Real‐World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell‐Based Assay
Said, Yana , Tran, Conlan , Rezavi, LuAnn, Sotirchos, Elias S. , Sotirchos, Elias S , Said, Yana , Caturegli, Patrizio , Flanagan, Eoin P.

Annals of Clinical and Translational Neurology | May 14, 2025 | Volume: 12 | Issue: 8 | Pages: 1725-1726

10.1002/acn3.70061 | PMID 40368601 Get It